Identification of a Wilms’ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes

[1]  Z. Berneman,et al.  Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia , 2012, Leukemia.

[2]  T. Kyo,et al.  Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease , 2012, Leukemia.

[3]  Z. Berneman,et al.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. , 2012, The oncologist.

[4]  Z. Berneman,et al.  Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers , 2011, Human vaccines.

[5]  Andrew R. Jones,et al.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..

[6]  H. Goossens,et al.  Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination , 2010, Proceedings of the National Academy of Sciences.

[7]  Y. Takeda,et al.  A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. , 2010, Anticancer research.

[8]  M. Juan,et al.  Reassessing the role of HLA‐DRB3 T‐cell responses: Evidence for significant expression and complementary antigen presentation , 2009, European journal of immunology.

[9]  L. Old,et al.  Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire , 2009, Clinical Cancer Research.

[10]  E. Thiel,et al.  A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.

[11]  I. Kawase,et al.  A WT1 protein‐derived, naturally processed 16‐mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1‐specific Th1‐type CD4+ T cells , 2008, Microbiology and immunology.

[12]  K. Rezvani,et al.  Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. , 2007, Blood.

[13]  Mario Roederer,et al.  A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles , 2005, Nature Medicine.

[14]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Thomson,et al.  High resolution HLA-DRB1 identification of a Caucasian population. , 2004, Human immunology.